Medicine Grand Rounds - Heart Failure with Preserved Ejection Fraction - A Misunderstood Disease in Search of a Therapy

Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Heart Failure with Preserved Ejection Fraction - A Misunderstood Disease in Search of a Therapy, 2/12/2021 8:00:00 AM - 2/12/2024 9:00:00 AM, Dr. Solomon describes the syndrome of Heart Failure with Preserved Ejection Fraction (HFpEF) and the evolving understanding of its pathophysiology, from the concept of “diastolic dysfunction” to a more complex and multifaceted condition. HFpEF is primarily a clinical diagnosis supported by a standard evaluative process, but easily misdiagnosed due to the overlap of many of its symptoms and signs with conditions with which it is frequently comorbid. Many therapeutic options exist, with diuretics, diet, and exercise well established and a growing body of emerging evidence for other pharmacologic interventions.

Presenter
Scott D. Solomon, MD
The Edward D. Frohlich Distinguished Chair
Professor of Medicine, Harvard Medical School
Brigham and Women’s Hospital

About our presenter: 
Scott D. Solomon, MD is Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women’s Hospital. He received his A.B. from Williams College and his M.D. from Harvard Medical School.

Dr. Solomon’s research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk, and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction.

Learning Outcome(s)
Participants will be able to discuss the epidemiology and pathophysiology of HFpEF, emerging concepts about heart failure phenotypes, and the current and emerging therapeutic options in patients with HFpEF.

Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported the following financial interest or relationship* with various companies/organizations. The Planning Committee member role was resolved by altering the individual’s control over content about the products or services of the commercial interest by Marc Bertrand, MD, Associate Dean for GME (as alternate for vacant Associate Dean for CME position). The speaker role has been resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.

* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.

* Scott D. Solomon, MD ~ receives grant support from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, and Theracos.  He also does consulting for the following companies: Abbott, Actelion, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GSK, Ironwood, Lilly, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Sanofi-Pasteur, Tenaya, Dinaqor, Tremeau, CellProThera, Moderna, and American Regent.

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Bibliographic Material
• See presentation for bibliographic sources to allow for further study.